These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 32543358)
1. Review and Prospect of Tissue-agnostic Targeted Strategies in Anticancer Therapies. Peng Y; Tao H; Gao Y; Yang Y; Chen Z Curr Top Med Chem; 2021; 21(5):404-425. PubMed ID: 32543358 [TBL] [Abstract][Full Text] [Related]
2. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine. Seligson ND; Knepper TC; Ragg S; Walko CM Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906 [TBL] [Abstract][Full Text] [Related]
3. The FDA Oncology Center of Excellence and precision medicine. Goldberg KB; Blumenthal GM; McKee AE; Pazdur R Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511 [TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
5. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939 [TBL] [Abstract][Full Text] [Related]
6. Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Vranic S; Gatalica Z Biomol Biomed; 2024 Jul; 24(4):673-675. PubMed ID: 38656302 [TBL] [Abstract][Full Text] [Related]
7. A systematic analysis of FDA-approved anticancer drugs. Sun J; Wei Q; Zhou Y; Wang J; Liu Q; Xu H BMC Syst Biol; 2017 Oct; 11(Suppl 5):87. PubMed ID: 28984210 [TBL] [Abstract][Full Text] [Related]
8. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126 [TBL] [Abstract][Full Text] [Related]
9. Tissue-Agnostic Drug Development: A New Path to Drug Approval. Thein KZ; Lemery SJ; Kummar S Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971 [TBL] [Abstract][Full Text] [Related]
11. The evolving landscape of tissue-agnostic therapies in precision oncology. Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R CA Cancer J Clin; 2024; 74(5):433-452. PubMed ID: 38814103 [TBL] [Abstract][Full Text] [Related]
12. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Vranic S; Basu GD; Hall DW; Gatalica Z Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315 [TBL] [Abstract][Full Text] [Related]
13. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States. Nakayama H; Matsumaru N; Tsukamoto K Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823 [TBL] [Abstract][Full Text] [Related]
14. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489 [TBL] [Abstract][Full Text] [Related]
15. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. Adashek JJ; Subbiah V; Kurzrock R Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795 [TBL] [Abstract][Full Text] [Related]
16. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. Marquart J; Chen EY; Prasad V JAMA Oncol; 2018 Aug; 4(8):1093-1098. PubMed ID: 29710180 [TBL] [Abstract][Full Text] [Related]
17. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities. Barone A; Casey D; McKee AE; Reaman G Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772 [TBL] [Abstract][Full Text] [Related]
18. TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options. Gershkovich P; Platt J; Knopf J; Tasoulis MK; Shi W; Pusztai L; Hatzis C JCO Clin Cancer Inform; 2018 Dec; 2():1-13. PubMed ID: 30652574 [TBL] [Abstract][Full Text] [Related]
19. Analysis of FDA approvals of targeted anticancer combination regimens. Brown VT; Cho V; Parkey S Am J Health Syst Pharm; 2017 Dec; 74(23):1938-1942. PubMed ID: 29167134 [No Abstract] [Full Text] [Related]
20. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]